A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib 100 mg b.i.d. versus teriflunomide 14 mg q.d. in participants with relapsing multiple sclerosis, followed by extended treatment with open-label remibrutinib

Is this Study for You?

Let's Get Started!



Type of Study



Brain Imaging Center (BIC)
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital

Principal Investigator
Photograph of Enrique Alvarez,  MD, PhD

Enrique Alvarez, MD, PhD

Study ID

Protocol Number: 21-4825

More information available at ClinicalTrials.gov: NCT05147220

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers